These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 22973724)

  • 1. [Proteomics for biomarker development toward personalized medicine].
    Kondo T
    Rinsho Byori; 2012 Jul; 60(7):644-9. PubMed ID: 22973724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Biomarker development by cancer proteomics].
    Kondo T
    Nihon Rinsho; 2012 May; 70(5):754-8. PubMed ID: 22619997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteomic approach toward personalized sarcoma treatment: lessons from prognostic biomarker discovery in gastrointestinal stromal tumor.
    Kondo T; Suehara Y; Kikuta K; Kubota D; Tajima T; Mukaihara K; Ichikawa H; Kawai A
    Proteomics Clin Appl; 2013 Jan; 7(1-2):70-8. PubMed ID: 23281253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical proteomics: from biomarker discovery and cell signaling profiles to individualized personal therapy.
    Calvo KR; Liotta LA; Petricoin EF
    Biosci Rep; 2005; 25(1-2):107-25. PubMed ID: 16222423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer proteomics.
    Tan HT; Lee YH; Chung MC
    Mass Spectrom Rev; 2012; 31(5):583-605. PubMed ID: 22422534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic value of pfetin: a validation study in gastrointestinal stromal tumors using a commercially available antibody.
    Kubota D; Mukaihara K; Yoshida A; Suehara Y; Saito T; Okubo T; Gotoh M; Orita H; Tsuda H; Kaneko K; Kawai A; Kondo T; Sato K; Yao T
    Jpn J Clin Oncol; 2013 Jun; 43(6):669-75. PubMed ID: 23619989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pfetin as a prognostic biomarker of gastrointestinal stromal tumors revealed by proteomics.
    Suehara Y; Kondo T; Seki K; Shibata T; Fujii K; Gotoh M; Hasegawa T; Shimada Y; Sasako M; Shimoda T; Kurosawa H; Beppu Y; Kawai A; Hirohashi S
    Clin Cancer Res; 2008 Mar; 14(6):1707-17. PubMed ID: 18347171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarker assay translation from discovery to clinical studies in cancer drug development: quantification of emerging protein biomarkers.
    Lee JW; Figeys D; Vasilescu J
    Adv Cancer Res; 2007; 96():269-98. PubMed ID: 17161683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation study on pfetin and ATP-dependent RNA helicase DDX39 as prognostic biomarkers in gastrointestinal stromal tumour.
    Kubota D; Okubo T; Saito T; Suehara Y; Yoshida A; Kikuta K; Tsuda H; Katai H; Shimada Y; Kaneko K; Kawai A; Kondo T
    Jpn J Clin Oncol; 2012 Aug; 42(8):730-41. PubMed ID: 22723667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteomics in prostate cancer biomarker discovery.
    Larkin SE; Zeidan B; Taylor MG; Bickers B; Al-Ruwaili J; Aukim-Hastie C; Townsend PA
    Expert Rev Proteomics; 2010 Feb; 7(1):93-102. PubMed ID: 20121479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Possibilities and limitations of stratified medicine based on biomarkers and targeted therapies in oncology].
    Ludwig WD
    Z Evid Fortbild Qual Gesundhwes; 2012; 106(1):11-22. PubMed ID: 22325103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteomic approaches to the discovery of cancer biomarkers for early detection and personalized medicine.
    Honda K; Ono M; Shitashige M; Masuda M; Kamita M; Miura N; Yamada T
    Jpn J Clin Oncol; 2013 Feb; 43(2):103-9. PubMed ID: 23248327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of proteomic technologies for prostate cancer detection, prognosis, and tailored therapy.
    Fredolini C; Liotta LA; Petricoin EF
    Crit Rev Clin Lab Sci; 2010; 47(3):125-38. PubMed ID: 20858067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer: a proteomic disease.
    Li G; Xiao Z; Liu J; Li C; Li F; Chen Z
    Sci China Life Sci; 2011 May; 54(5):403-8. PubMed ID: 21455689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implications of salivary proteomics in drug discovery and development: a focus on cancer drug discovery.
    Hu S; Yen Y; Ann D; Wong DT
    Drug Discov Today; 2007 Nov; 12(21-22):911-6. PubMed ID: 17993408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pfetin as a prognostic biomarker for gastrointestinal stromal tumor: validation study in multiple clinical facilities.
    Kubota D; Orita H; Yoshida A; Gotoh M; Kanda T; Tsuda H; Hasegawa T; Katai H; Shimada Y; Kaneko K; Kawai A; Kondo T
    Jpn J Clin Oncol; 2011 Oct; 41(10):1194-202. PubMed ID: 21903705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteomic approaches in lung cancer biomarker development.
    Cho JY; Sung HJ
    Expert Rev Proteomics; 2009 Feb; 6(1):27-42. PubMed ID: 19210125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of 2D-DIGE in cancer proteomics toward personalized medicine.
    Kondo T; Hirohashi S
    Methods Mol Biol; 2009; 577():135-54. PubMed ID: 19718514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional genomics and proteomics in the clinical neurosciences: data mining and bioinformatics.
    Phan JH; Quo CF; Wang MD
    Prog Brain Res; 2006; 158():83-108. PubMed ID: 17027692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.